Guselkumab
Based on 1 Customer Validation
Guselkumab is a recombinant human IgG1 monoclonal antibody against the IL-23p19 subunit. Guselkumab binds to human and cynomolgus monkey IL-23 with Kd values of 3.3 and 1.9 pmol/L, respectively. Guselkumab inhibits production of cytokines lying downstream of the IL-23 signaling pathway and can be used for psoriatic arthritis research.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- Reinheit : 99.34%
- CAS. Nr.: 1350289-85-8
- Molecular Weight:144.8 kDa
-
Speicherung:Shipping with dry ice
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biologische Aktivität
-
Chemical Information
- Protokoll
- Reinheit & Dokumentation
- Verweise
-
Help & FAQs
-
HY-P99248
RisankizumabIL-23 IgG Monoclonal Antibody -
HY-P9909
Ustekinumab -
HY-P99737
MirikizumabIL-23 Antibody -
HY-P99256
TildrakizumabAnti-IL-23 mAb -
HY-P99244
FezakinumabIL-22 Antibody -
HY-P99025
LebrikizumabIL-13 Inhibitor -
HY-P9924
IxekizumabIL-17A Antagonist -
HY-P990007
TulisokibartAnti-TNFSf15/TL1A Antibody -
HY-P990006
DuvakitugAnti-TNFSf15/TL1A Antibody -
HY-19569
UpadacitinibJAK1 Inhibitor -
HY-P9926
DupilumabIL-4Rα Inhibitor -
HY-P99053
TralokinumabIL-13 Inhibitor
Biologische Aktivität
Beschreibung
Isotype
Human IgG1 lambda2
Recommend Isotype Controls
Species Reactivity
Human
IC50 & Target
[1]|
IL-23 .06 nM (IC50) |
In Vitro
Guselkumab inhibits IL-23 (0.5 or 1 ng/mL)-mediated production of Th17 cytokines IL17A, IL-17F, and IL-22 in mouse splenocyteswith IC50 ranging 0.016-0.080 nM. And, it inhibits IL-23 (10 or 100 ng/mL)-mediated production of IL-10 in human NKL cells. Guselkumab has no effect on IL-12 (0.1 ng/mL)-mediated production of interferon γ (IFNγ) in NK92MI cells. [1].Guselkumab combines with IBI112 blocks IL-23-induced STAT3 phosphorylation, and Guselkumab blocks IL-23-induced STAT3 phosphorylation with an IC50 value of 102.1100±2.0053 nM[2].. Guselkumab blocks hIL-23-induced mIL-17 production in a dose-dependent manner, exhibiting an IC50 of 4.9743 ±1.2847 nM. In another experiment, Guselkumab also blocks IL-17F production in cynomolgus monkeys with an IC50 of 16.7950 nM[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | 2011-05 | PHASE1 |
Gene ID
Accession
Conjugated
Unconjugated
Reconsititution
The product can be reconstituted/diluted with sterile PBS or saline.
Format
-
Human IgG1 lambda2
Anwendung
ELISA, FACS, Functional assay
Verified Bioactivity
-
Immobilized huIL-p19-N-His & huIL-12 p40 can bind Guselkumab. The EC50 for this effect is 21.95 ng/mL.
Chemical Information
-
CAS. Nr. 1350289-85-8
-
Appearance Liquid
-
Molecular Weight 144.8 kDa
-
Color Colorless to light yellow
-
SMILES
[Guselkumab]
-
Synonyms
CNTO 1959
-
Versand
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Speicherung
Please store the product under the recommended conditions in the Certificate of Analysis.
Reinheit & Dokumentation
-
Data Sheet (257 KB)
-
SDS (394 KB)
- English - EN (394 KB)
- Français - FR (394 KB)
- Deutsch - DE (394 KB)
- Norwegian - NO (394 KB)
- Español - ES (394 KB)
- Swedish - SV (394 KB)
- Italian - IT (394 KB)
- Korean - KR (394 KB)
- Portuguese - PT (394 KB)
-
Inhibitory Antibodies User Guide (603 KB)
Verweise
Calculators
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)
Guselkumab Related Classifications
HY-P9931 Related Classifications
Powered by Bioz